Appili Therapeutics Inc (APLI)

0.0500
-0.0050(-9.09%)
  • Volume:
    19,729
  • Bid/Ask:
    0.0500/0.0550
  • Day's Range:
    0.0500 - 0.0500

APLI Overview

Prev. Close
0.055
Day's Range
0.05-0.05
Revenue
1.39M
Open
0.05
52 wk Range
0.035-0.18
EPS
-0.119
Volume
19,729
Market Cap
5.46M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
261,948
P/E Ratio
-0.336
Beta
0.868
1-Year Change
-64.29%
Shares Outstanding
121,266,120
Next Earnings Date
Feb 14, 2023
What is your sentiment on Appili Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Appili Therapeutics Inc News

Appili Therapeutics Inc Analysis

Appili Therapeutics Inc Company Profile

Appili Therapeutics Inc Company Profile

Employees
8
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA03783R1073
  • CUSIP:03783R107

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell